Neurosurgical Management of Gliomas
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 1394
Special Issue Editor
2. INSERM, CHU-Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, Université de Lille, F-59000 Lille, France
Interests: intraoperative MRI; fluorescence-guided surgery; photodynamic therapy
Special Issue Information
Dear Colleagues,
Neurosurgical management plays a critical role in the treatment of gliomas, which are tumors that arise from the glial cells in the brain. The primary objective of neurosurgical intervention is to safely remove as much of the tumor as possible while preserving neurological function.
The management of gliomas involves a multidisciplinary approach, with neurosurgeons, oncologists, radiologists, and other specialists working together to develop an individualized treatment plan for each patient.
Surgery is often the first-line treatment for gliomas, aiming to achieve maximal safe resection. Moreover it provides material for the histo-molecular analysis of the tumor leading to the best medical management. The extent of tumor removal depends on various factors, such as the tumor location, size, and proximity to vital brain structures and may require different tools as intraoperative monitoring in awake condition, intraoperative imaging or fluorescence-guided surgery. The goal is to remove as much of the tumor as possible to alleviate symptoms, reduce tumor burden, and potentially improve patient outcomes.
This special issue hopes to provide some implications for future clinical practice by exploring the neurosurgical management of gliomas.
Dr. Nicolas Reyns
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurosurgery
- neurological surgery
- brain surgery
- gliomas
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.